查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863372

基因融合检测市场按技术、检体类型、应用和最终用户划分－2025-2032年全球预测

Gene Fusion Testing Market by Technology, Sample Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，基因融合检测市场将成长至 12.5788 亿美元，复合年增长率为 12.76%。

关键市场统计数据
基准年 2024 4.8095亿美元
预计年份：2025年 5.4132亿美元
预测年份 2032 1,257,880,000 美元
复合年增长率 (%) 12.76%

基因融合检测与临床路径、转化研究以及诊断生态系统中相关人员决策的相关性：一个简明策略框架。

基因融合检测已成为现代分子诊断和转化研究的核心组成部分，重塑了肿瘤学、血液学和罕见疾病等临床诊疗路径中的决策过程。检测方法设计和分析流程的进步，已将检测方式从单基因和细胞遗传学方法转变为整合分子谱分析，从而揭示可靶向的融合基因、抗药性机制和疾病亚型。随着标靶治疗在临床上的广泛应用，精准识别基因融合对于患者筛选、治疗监测以及精准医疗试验的入组合格至关重要。

本摘要对技术演进、监管和贸易影响、细分市场趋势、区域应用模式、竞争动态以及对行业相关人员的建议进行了摘要分析。它基于实验室工作流程优化、定序方法兴起以及检体处理限制与检测灵敏度之间相互作用的实证数据，为决策者提供了一个策略框架下的概览。本概要重点阐述了哪些领域的投资、合作和营运重点能够显着提升临床效用和商业性吸引力。

本文重点介绍了诊断实验室、临床中心、製药开发公司和研究机构之间的综合测试策略和多学科合作如何重新定义从发现到临床实施的路径，为读者提供了一个在科学技术能力与市场和监管现实的交汇处创造创新和竞争优势机会的实用观点。

技术融合、监管政策明确化和临床证据将如何加速基因融合检测的标准化和临床应用？

基因融合检测领域已发生变革性转变，这主要得益于技术融合、监管成熟和不断涌现的临床证据。过去以细胞遗传学检测和单一分析方法为主，而如今则更重视结合正交验证方法和高解析度分析的多模态策略。次世代定序技术促进了这项转变，不仅能够广泛检测标准和新型融合基因，还能整合实验室工作流程，并缩短检测时间。

同时，融合检测的临床效用正从最初的诊断分类扩展到治疗方案选择、微量残存疾病评估以及伴随诊断的开发。检体处理技术的进步也促进了这一发展，包括改进从福马林固定、石蜡包埋组织中提取核酸的方法以及优化循环核酸的血浆通讯协定，这些进步共同提高了检测的产量，并扩大了非侵入性检测的合格患者范围。

市场进入驱动因素，例如更完善的报销框架和实验室自建检测 (LDT) 和体外诊断 (IVD) 的明确监管路径，正在推动医院和独立实验室采用先进的检测方法。此外，随着药物研发越来越依赖分子特征明确人群的招募，诊断开发商和製药公司之间的合作也不断加强。总而言之，这些变化标誌着一个成熟的生态系统正在形成，在这个生态系统中，技术能力、临床需求和商业性奖励相互协调，加速基因融合检测的标准化和规模化应用。

评估2025年美国关税对基因融合检测价值链的供应链、筹资策略和业务永续营运的影响

美国将于2025年实施关税，这给全球融合检测供应链中的相关人员带来了新的挑战。由于成本结构的变化和供应风险评估的更新，采购团队表示，试剂采购、设备购买和耗材供应流程都受到了更严格的审查。实验室和製造商正在评估多种采购策略和库存缓衝，以缓解短期采购波动，同时确保为患者提供持续的检测服务。

除了采购之外，关税环境也促使企业对区域製造地和分销网络进行策略性重新评估。一些公司正在加快关键零件的在地化生产，或寻求与国内供应商建立合作关係，以降低跨境关税风险。监管团队也预计，由于零件替换，产品可能需要重新认证，这推动了品质保证、监管和供应链部门之间更紧密的合作。

临床医生和实验室负责人强调，维持检测效能和结果週转时间是重中之重。因此，营运调整的重点是优先采用检验的替代方案和互换性测试，以避免中断临床工作流程。同时，销售团队正在与医疗机构和参考实验室审查定价和合约模式，以便根据客户谈判和竞争环境来承担或转嫁成本影响。整体而言，关税主导的环境正在迫使产业采取更具韧性和灵活性的姿态，强调供应链透明度、区域能力和跨职能协作，以确保患者照护的连续性。

针对特定领域的诊断和商业性洞察，重点介绍整个检测过程中的技术差异、检体限制、临床应用和最终用户工作流程要求。

深入了解特定细分领域的趋势对于确定基因融合检测领域的投资和发展重点至关重要。技术评估必须反映每种方法的独特优点和限制：萤光原位杂合反应(FISH)、免疫组织化学 (IHC)、次世代定序(NGS) 和 RT-PCR。次世代定序本身又分为标靶基因panel检测、转录组定序和全基因测序，每种方法在范围、分析复杂性和基础设施需求方面各不相同。每种技术途径都需要不同的检验方法、生物资讯学流程和终端使用者培训，以确保临床层级的结果解读和可重复性。

检体类型对操作设计和检测的可近性有显着影响。基于血液的工作流程需要采用能够保存循环核酸的血浆和血清处理通讯协定，而组织工作流程则必须同时考虑福马林固定、石蜡包埋的样本和冷冻组织，这两种样本在核酸完整性、週转时间和组织病理学整合方面各有优劣。应用主导的细分錶明，血液学、肿瘤学和罕见疾病应用场景对灵敏度、特异性和报告粒度有着不同的临床阈值要求。在血液学领域，白血病和淋巴瘤检测有助于治疗方法分层和微量残存疾病评估，而乳癌、结直肠癌、肺癌和前列腺癌等肿瘤学应用则优先考虑检测具有治疗价值的融合基因和抗药性机制。罕见疾病应用，包括发育障碍和神经肌肉疾病，通常需要更广泛的转录组分析和专门的解读框架。

终端用户差异化进一步影响商业性策略和服务设计。院内和独立诊断实验室优先考虑的是检测量优化和检测方法标准化。医院（包括住院部和门诊部）优先考虑的是快速报告检测结果并与电子健康记录 (EHR) 系统整合。从生技公司到大型製药企业，製药公司寻求伴随诊断合作伙伴和严格的分析检验，以支持临床试验。研究机构（包括学术实验室和商业实验室）推动早期发现和方法开发，这些成果可进入临床研发流程。了解这些相互关联的细分市场有助于更精准地确定产品功能、市场通路和合作模式的优先级，从而使技术能力与终端用户的工作流程和结果解读需求相匹配。

区域比较分析塑造了美洲、欧洲、中东和非洲以及亚太地区的采用趋势、合作模式和营运策略。

区域趋势对融合检测相关人员的采纳路径、伙伴关係机会和营运重点有显着影响。在美洲，广泛的诊断实验室网络以及临床中心和药物研发计画之间的高度协作塑造了该地区的服务提供模式。该地区倾向于优先采用先进的定序方法，并建立与药物研发时间表和法规结构相符的伴随诊断。医院、参考实验室和产业合作伙伴之间的合作联盟通常能够进行多中心检验研究，并加速临床应用。

欧洲、中东和非洲地区（EMEA）情况复杂多样，既有高度集中的国家级参考实验室系统，也有分散的医院网路。各医疗系统的采购模式和报销途径差异巨大，而监管协调和跨境临床合作正在推动某些市场采用新技术。该地区的相关人员通常致力于证明成本效益、临床效用以及与不同医疗IT基础设施基础设施的互通性，以期获得公立和私立医疗机构的认可。

全部区域基础设施的快速投资以及政府对精准医疗倡议的大力支持，正推动学术研究和商业性检测能力的双双成长。在多个市场，实验室正在建立本地化生产能力，以拓展定序的服务并减少对进口的依赖。区域公共卫生重点和特定族群的基因组特征也影响检测方法的选择和检验策略，从而推动个人化检测方案的製定，以反映当地的临床需求和检体可用性。为了因应这些区域差异，差异化的合作模式和策略投资计画对于优化市场准入、建立伙伴关係和服务交付至关重要。

竞争格局分析重点在于平台差异化、协同创新和策略伙伴关係，以推动临床整合和市场渗透。

基因融合检测领域的竞争格局由成熟的诊断公司、专业的定序平台提供者以及专注于检测化学和生物资讯学的新兴创新者共同构成​​。领先的诊断开发人员正致力于开发端到端解决方案，将经过检验的检测方法与强大的资讯科学、监管文件以及为医院和参考实验室客户量身定制的服务模式相结合。平台提供者则透过提高通量、提升读取准确性以及与实验室资讯管理系统无缝整合来不断提升自身竞争力，从而最大限度地减少工作流程中断。

同时，一些创新参与企业正透过转录组层级的方法和新型样品製备化学技术，不断突破检测灵敏度和广度的极限，从而能够检测复杂或罕见的融合事件。这些进展通常源自于学术合作或商业实验室，之后才被应用于临床实践，凸显了研究机构与商业机构之间建立策略联盟的重要性。製药公司透过委託进行分析检验研究和共同开发伴随诊断试剂，继续发挥关键的合作作用，以支持标靶治疗计画。

併购、策略联盟和分销协议是拓展全球业务、应对供应链脆弱性的常用方式。能够有效结合强大的技术基础、经临床检验的效用和灵活的商业模式的公司，在与医疗系统和临床实验申办者建立长期合作关係方面更具优势。最终，那些在创新、严格的监管合规性、营运可靠性和明确的临床疗效证据之间取得平衡的企业，将获得竞争优势。

为组织机构提供切实可行的策略行动，以增强韧性、加速临床应用并提升诊断和治疗生态系统内的协作价值创造。

产业领导者应优先考虑一系列切实可行的倡议，以增强韧性、加速临床应用并释放融合检测生态系统的新价值。首先，投资于模组化、检验的工作流程，使实验室能够逐步采用基于定序的检测方法，从而降低准入门槛，同时保持分析的严谨性。这种方法有助于逐步升级并减少训练阻力，从而促进医院和独立实验室的广泛应用。

其次，提高供应链透明度和多元化筹资策略可以降低关税和供应中断的风险。确保关键试剂的合格二级供应商，并探索区域製造伙伴关係，可以最大限度地减少前置作业时间的波动，保障检测的连续性。与筹资策略并行，相关人员应建立健全的变更控制通讯协定，以便在不影响效能的前提下对替代零件进行预先认证。

第三，企业应深化与药物研发企业和临床网路的合作，促进伴随诊断的共同开发和前瞻性检验研究，以证明其临床效用。将检测设计与治疗开发平臺结合，可以加快患者获得标靶治疗的速度，并增强商业性价值提案。最后，增加对临床医师教育和标准化报告范本的投入，可以改善检测结果的解读，增强临床医师的信心，并促进检测结果顺利融入治疗决策过程。综合运用这些措施，将使企业能够灵活应对外部衝击，同时掌握技术创新和不断变化的临床需求所带来的机会。

采用透明、多方面的研究途径，结合相关利益者访谈、技术文献和营运案例研究，以支持可操作的研究结果和建议。

本研究综合分析采用多方面方法，从技术、临床和商业性观点进行三角验证。主要资料来源包括实验室主任、分子病理学家、采购人员和临床试验相关人员的结构化访谈，以及与检测方法开发人员和平台提供者的面对面咨询。次要分析涵盖同侪审查文献、监管指导文件、技术白皮书和产品手册，检验分析方法和监管方面的考量。在适用情况下，来自实验室的匿名营运案例研究为工作流程实施和检验中遇到的挑战提供了真实案例背景。

透过对技术性能特征、检体处理通讯协定和最终用户需求进行系统性的交叉检验，确保了分析的严谨性。调查方法优先考虑同侪审查的证据和关键相关人员的证词，以确保建议既体现科学有效性，又具有实际操作可行性。对区域法规环境和报销环境的考量为区域洞察奠定了基础，而供应链评估则整合了采购数据和供应商访谈，以评估薄弱环节和缓解措施。

我们认识到任何综合分析都存在固有的局限性，包括不同实验室报告标准的差异以及区域监管解释的差异。为了克服这些限制，我们的方法强调资料来源的透明度、对假设的明确记录，以及提供详细的调查方法，包括访谈指南、纳入标准和检验查核点。这种方法使相关人员能够对基础证据充满信心，同时又能根据自身俱体的操作环境调整研究结果。

关于如何协调技术能力、营运韧性和合作伙伴关係，以充分发挥基因融合检测的临床潜力，得出综合策略结论。

基因融合检测技术的成熟是技术创新、临床需求以及诊断开发商、医疗系统和製药合作伙伴之间战略合作共同作用的结果。随着基于定序的方法日益普及和检体处理技术的进步，将可靠的融合基因检测纳入常规诊断的机会从未如此清晰。然而，要充分发挥这一潜力，需要检验的工作流程、稳健的供应链以及对合作证据产生的持续投入，以证明其在不同患者群体中的临床效用。

那些现在就将检测设计与终端用户工作流程相匹配、实现供应链网络多元化并与治疗药物开发商建立战略伙伴关係的相关人员，将更有利于确保运营的连续性，同时充分利用科学进步。不断变化的监管环境和报销体系重视清晰的证据和跨部门合作，因此，儘早与临床和监管相关人员开展合作将成为一项竞争优势。总之，基因融合检测生态系统已做好持续整合临床应用的准备，而那些推动技术、商业性和营运一体化策略的机构将主导从发现到改善患者疗效的下一阶段。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 采用多重次世代定序检测方法同时检测肿瘤患者的基因融合
  • 将液态生物检体平台整合到癌症筛检计画中，用于非侵入性基因融合检测。
  • 标靶治疗的扩展推动了个人化医疗中对精确基因融合分析的需求。
  • 开发基于人工智慧的生物资讯流程，以提高临床诊断中基因融合识别的准确性
  • 实验室开发的检测方法不断发展，可提供快速基因融合分析，从而在诊疗现场为肿瘤决策提供支援。
  • 诊断公司和製药公司之间的合作正在扩大，以共同开发基于融合基因的治疗性生物标记。
  • 新型基因融合检测套件获监理机关核准，加速进入新兴市场
  • RNA多重PCR检测在固态肿瘤中罕见融合转录本的全面检测中的应用日益广泛
  • 自动化样本到报告平台的出现将缩短临床实验室基因融合分析的周转时间
  • 推动社区医院基因融合检测分散式检查网路扩张的投资趋势

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 基因融合检测市场（依技术划分）

  • 萤光原位杂合反应
  • 免疫组织化学
  • 次世代定序
    • 标靶次世代定序
    • 转录定序
    • 全基因测序
  • 逆转录聚合酵素链锁反应

9. 依检体类型分類的基因融合检测市场

  • 血
    • 电浆
    • 血清
  • 组织
    • 福马林固定石蜡包埋
    • 新鲜冷冻组织

第十章 基因融合检测市场（依应用领域划分）

  • 血液学
    • 白血病
    • 淋巴瘤
  • 肿瘤学
    • 乳癌
    • 大肠直肠癌
    • 肺癌
    • 摄护腺癌
  • 罕见疾病
    • 发展障碍
    • 神经肌肉疾病

第十一章 基因融合检测市场（依最终用户划分）

  • 诊断实验室
    • 医院检查室
    • 独立检验机构
  • 医院
    • 住院设施
    • 门诊部
  • 製药公司
    • 生技公司
    • 大型製药公司
  • 研究所
    • 学术机构
    • 私人研究机构

第十二章 基因融合检测市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 基因融合检测市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国基因融合检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd
    • Agilent Technologies, Inc.
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • NanoString Technologies, Inc.
    • BGI Genomics Co., Ltd.
    • Foundation Medicine, Inc.
    • Archer DX, Inc.
Product Code: MRR-2E76C3E47FBF

The Gene Fusion Testing Market is projected to grow by USD 1,257.88 million at a CAGR of 12.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 480.95 million
Estimated Year [2025] USD 541.32 million
Forecast Year [2032] USD 1,257.88 million
CAGR (%) 12.76%

Concise strategic framing of gene fusion testing relevance to clinical pathways, translational research, and stakeholder decision-making in diagnostic ecosystems

Gene fusion testing has emerged as a pivotal component of modern molecular diagnostics and translational research, reshaping clinical decision-making across oncology, hematology, and rare disease pathways. Advances in assay design and analytic pipelines have shifted testing from single-gene or cytogenetic approaches toward integrated molecular profiles that reveal actionable fusions, resistance mechanisms, and disease subtypes. As the clinical adoption of targeted therapies expands, precise identification of gene fusions has become essential for patient selection, therapeutic monitoring, and eligibility for precision medicine trials.

This summary synthesizes technological evolution, regulatory and trade influences, segment-level dynamics, regional adoption patterns, competitive movements, and recommendations for industry stakeholders. It draws on evidence of laboratory workflow optimization, the rising role of sequencing-based modalities, and the interplay between sample handling constraints and assay sensitivity. The goal is to provide decision-makers with a concentrated, strategically framed narrative that highlights where investment, partnership, and operational focus can materially improve clinical utility and commercial traction.

Throughout the document, emphasis is placed on how integrated testing strategies and cross-disciplinary collaboration between diagnostic laboratories, clinical centers, pharmaceutical developers, and research institutions are redefining pathways from discovery to clinical implementation. In doing so, readers will gain an actionable perspective on where scientific capability intersects with market and regulatory realities to create opportunities for innovation and competitive differentiation.

How technological convergence, regulatory clarity, and clinical evidence are accelerating standardization and broader clinical adoption of gene fusion testing

The landscape for gene fusion testing has undergone transformative shifts driven by technological convergence, regulatory maturation, and evolving clinical evidence. Historically dominated by cytogenetic and single-analyte assays, the field now favors multi-modal strategies that combine orthogonal confirmation with high-resolution profiling. Next-generation sequencing has catalyzed this transition, enabling broader detection of canonical and novel fusions while allowing laboratories to consolidate workflows and reduce time-to-result variability.

Concurrently, the clinical utility of fusion detection has expanded beyond initial diagnostic categorization to include therapy selection, minimal residual disease evaluation, and companion diagnostic development. This evolution is complemented by improvements in sample processing, such as enhanced nucleic acid extraction from formalin-fixed paraffin embedded tissue and optimized plasma protocols for circulating nucleic acids, which collectively increase assay yield and broaden patient eligibility for noninvasive testing.

Market access drivers, including more nuanced reimbursement frameworks and clearer regulatory pathways for laboratory-developed tests and in vitro diagnostics, have supported the adoption of advanced assays in hospital-based and independent laboratories alike. Partnerships between diagnostic developers and pharmaceutical companies have also intensified as drug development increasingly predicates enrollment on molecularly defined populations. Taken together, these shifts indicate a maturing ecosystem where technological capability, clinical need, and commercial incentives align to accelerate the standardization and scaling of gene fusion testing.

Assessment of the 2025 United States tariff impacts on supply chains, procurement strategies, and operational resilience within gene fusion testing value chains

The introduction of United States tariffs in 2025 has created a new layer of complexity for stakeholders operating in global supply chains for gene fusion testing. Procurement teams report increased scrutiny of reagent sourcing, instrument purchases, and consumable pipelines as cost profiles shift and supply risk assessments are updated. Laboratories and manufacturers are evaluating dual-sourcing strategies and inventory buffers to mitigate near-term procurement volatility while maintaining continuity of testing services for patients.

Beyond procurement, the tariff environment has prompted strategic re-evaluation of regional manufacturing footprints and distribution networks. Some companies have accelerated localization of critical component manufacturing or pursued partnerships with domestic suppliers to reduce exposure to cross-border duties. Regulatory teams are also anticipating potential product requalification needs associated with component substitutions, driving closer collaboration between quality assurance, regulatory affairs, and supply chain functions.

Clinicians and laboratory directors emphasize that maintaining assay performance and turnaround times remains paramount; therefore, operational adjustments prioritize validated alternatives and compatibility testing to avoid disruptions to clinical workflows. In parallel, commercial teams are recalibrating pricing and contracting models with health systems and reference laboratories to absorb or pass through cost impacts based on customer negotiations and competitive dynamics. Overall, the tariff-driven environment is forcing a more resilient and flexible industry posture, with an emphasis on supply chain transparency, localized capabilities, and cross-functional coordination to sustain uninterrupted patient care.

Segment-focused diagnostic and commercial insights highlighting technology distinctions, sample constraints, clinical applications, and end-user workflow requirements across the testing continuum

A granular appreciation of segment-specific dynamics is essential for targeting investment and development priorities within the gene fusion testing domain. When examining technology, assessments need to reflect the distinct advantages and constraints of Fluorescence In Situ Hybridization, Immunohistochemistry, Next Generation Sequencing, and RT-PCR, noting that Next Generation Sequencing itself comprises targeted panels, transcriptome sequencing, and whole genome sequencing approaches that vary in breadth, analytical complexity, and infrastructure requirements. Each technological path demands different validation approaches, bioinformatics pipelines, and end-user training to ensure clinical-grade interpretation and reproducibility.

Sample type considerations strongly influence operational design and test accessibility. Blood-based workflows require protocols for plasma and serum processing that preserve circulating nucleic acids, while tissue workflows must account for formalin-fixed paraffin embedded specimens and fresh frozen tissue, each presenting trade-offs in nucleic acid integrity, turnaround, and histopathology integration. Application-driven segmentation highlights that hematology, oncology, and rare disease use cases impose divergent clinical thresholds for sensitivity, specificity, and reporting granularity. Within hematology, testing for leukemia and lymphoma informs therapeutic stratification and minimal residual disease assessment, whereas oncology applications in breast, colorectal, lung, and prostate cancers prioritize the detection of actionable fusions and mechanisms of resistance. Rare disease applications, including developmental disorders and neuromuscular conditions, often require broader transcriptomic interrogation and specialized interpretation frameworks.

End-user differentiation further shapes commercial approaches and service design. Diagnostic laboratories, both hospital-based and independent, emphasize throughput optimization and assay standardization; hospitals, across inpatient facilities and outpatient clinics, value rapid turnaround and integration with electronic health records; pharmaceutical companies, spanning biotechnology firms and larger pharma organizations, seek companion diagnostic partnerships and rigorous analytical validation to support clinical trials; and research institutions, including academic centers and private research laboratories, drive early-stage discovery and method development that can translate into clinical pipelines. Understanding these interconnected segments enables more precise prioritization of product features, go-to-market channels, and collaborative models that align technical capability with end-user workflows and interpretive needs.

Comparative regional dynamics that shape adoption, partnership models, and operational strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific jurisdictions

Regional dynamics materially influence adoption pathways, partnership opportunities, and operational priorities for gene fusion testing stakeholders. In the Americas, service delivery models are shaped by an extensive network of diagnostic laboratories and a high degree of integration between clinical centers and pharmaceutical development programs. This region tends to prioritize rapid implementation of advanced sequencing modalities and the establishment of companion diagnostics that align with drug development timelines and regulatory frameworks. Collaborative consortia between hospitals, reference labs, and industry partners frequently enable multi-site validation studies and accelerated clinical adoption.

In Europe, Middle East & Africa, the landscape is heterogeneous, with pockets of highly centralized national reference laboratory systems coexisting alongside decentralized hospital networks. Regulatory harmonization efforts and cross-border clinical collaborations are driving wider adoption in select markets, while health system procurement models and reimbursement pathways vary significantly. Stakeholders in this region often focus on demonstrating cost-effectiveness, clinical utility, and interoperability with diverse health IT infrastructures to gain adoption across public and private providers.

Across Asia-Pacific, rapid infrastructure investment and strong government support for precision medicine initiatives have catalyzed growth in both academic research and commercial testing capacity. Laboratories in several markets are scaling sequencing-based services and developing localized manufacturing capabilities to reduce reliance on imports. Regional public health priorities and population-specific genomic characteristics also shape test selection and assay validation strategies, prompting tailored approaches that reflect local clinical needs and sample availability. These regional nuances necessitate differentiated engagement models and strategic investment plans to optimize market entry, partnerships, and service delivery.

Competitive landscape analysis emphasizing platform differentiation, collaborative innovation, and strategic partnerships that drive clinical integration and market traction

Competitive activity in the gene fusion testing arena is defined by a mix of established diagnostic companies, specialized sequencing platform providers, and emerging innovators focused on assay chemistry and bioinformatics. Leading diagnostic developers are investing in end-to-end solutions that combine validated assays with robust informatics, regulatory documentation, and service models tailored to hospital and reference laboratory customers. Platform providers continue to differentiate through throughput capabilities, read accuracy, and seamless integration with laboratory information management systems to minimize workflow interruption.

At the same time, innovative entrants are pushing the boundaries of sensitivity and breadth through transcriptome-level approaches and novel library preparation chemistries that enable detection of complex or rare fusion events. These advancements often emerge from academic collaborations and private research labs before being adopted in clinical settings, underscoring the importance of strategic partnerships between research institutions and commercial entities. Pharmaceutical companies remain key collaborators, commissioning analytical validation studies and co-developing companion diagnostics to support targeted therapy programs.

Mergers, strategic alliances, and distribution agreements are common mechanisms for scaling global presence and addressing supply chain vulnerabilities. Companies that successfully combine strong technical platforms, validated clinical utility, and flexible commercial models are better positioned to secure long-term relationships with health systems and trial sponsors. Ultimately, competitive advantage accrues to organizations that balance innovation with regulatory rigor, operational reliability, and clear evidence of clinical impact.

Practical strategic actions for organizations to enhance resilience, accelerate clinical adoption, and strengthen collaborative value creation across diagnostic and therapeutic ecosystems

Industry leaders should prioritize a series of actionable initiatives to strengthen resilience, accelerate clinical adoption, and unlock new value across the gene fusion testing ecosystem. First, investing in modular, validated workflows that allow laboratories to adopt sequencing-based assays incrementally can lower barriers to entry while preserving analytical rigor. This approach facilitates stepwise upgrades and reduces training friction, enabling broader uptake among hospital-based and independent laboratories.

Second, strengthening supply chain transparency and diversifying sourcing strategies will mitigate tariff and disruption risks. Establishing qualified secondary suppliers for critical reagents and exploring regional manufacturing partnerships can minimize lead-time variability and protect assay continuity. Parallel to procurement strategies, stakeholders should institute robust change-control protocols that preemptively qualify alternative components without compromising performance.

Third, companies should deepen collaborations with pharmaceutical developers and clinical networks to co-develop companion diagnostics and prospective validation studies that demonstrate clinical utility. Aligning assay design with therapeutic development pipelines can accelerate patient access to targeted therapies and enhance the commercial value proposition. Finally, investing in clinician-facing education and standardized reporting templates will improve test interpretation, increase clinician confidence, and facilitate smoother integration into treatment decision pathways. These combined actions will position organizations to respond nimbly to external shocks while capturing opportunities created by technological innovation and evolving clinical demand.

Transparent multi-method research approach combining stakeholder interviews, technical literature, and operational case studies to underpin actionable insights and recommendations

This research synthesis is grounded in a multi-method approach designed to triangulate technical, clinical, and commercial perspectives. Primary inputs include structured interviews with laboratory directors, molecular pathologists, procurement leads, and clinical trial stakeholders, complemented by direct consultation with assay developers and platform providers. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, technical whitepapers, and product manuals to validate analytical approaches and regulatory considerations. Where applicable, anonymized operational case studies from laboratories provided real-world context on workflow implementation and validation challenges.

Analytical rigor was maintained through methodical cross-validation of technology performance characteristics, sample handling protocols, and end-user requirements. The methodology prioritized peer-reviewed evidence and primary stakeholder testimony to ensure recommendations reflect both scientific validity and operational feasibility. Sensitivity to regional regulatory and reimbursement environments informed the regional insights, while supply chain assessments integrated procurement data and supplier interviews to evaluate vulnerability and mitigation options.

Limitations inherent to any synthesis are acknowledged, including variability in reporting standards across laboratories and differences in local regulatory interpretation. To address these constraints, the methodology emphasizes transparency in data sources, explicit documentation of assumptions, and the provision of methodological appendices that detail interview guides, inclusion criteria, and validation checkpoints. This approach enables stakeholders to adapt findings to their specific operational contexts with confidence in the underlying evidence base.

Integrated strategic conclusions on aligning technical capability, operational resilience, and collaborative partnerships to realize the full clinical potential of gene fusion testing

The maturation of gene fusion testing reflects a convergence of technological innovation, clinical necessity, and strategic alignment among diagnostic developers, health systems, and pharmaceutical partners. As sequencing-based approaches become more accessible and sample processing improves, the opportunity to embed robust fusion detection into routine diagnostics has never been clearer. However, realizing that potential requires deliberate investments in validated workflows, supply chain resilience, and collaborative evidence generation that demonstrates clinical utility across diverse patient populations.

Stakeholders that act now to align assay design with end-user workflows, diversify supply networks, and engage in strategic partnerships with therapy developers will be best positioned to capitalize on scientific advances while safeguarding operational continuity. The evolving regulatory and reimbursement landscape rewards clarity of evidence and cross-sector collaboration, making early engagement with clinical and regulatory stakeholders a competitive differentiator. In conclusion, the gene fusion testing ecosystem is poised for sustained clinical integration, and organizations that pursue coordinated technical, commercial, and operational strategies will lead the next phase of translation from discovery to improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of multiplex next-generation sequencing assays for simultaneous gene fusion detection in oncology patients
  • 5.2. Integration of liquid biopsy platforms for noninvasive detection of gene fusions in cancer screening programs
  • 5.3. Expansion of targeted therapies driving demand for precise gene fusion profiling in personalized medicine
  • 5.4. Development of AI-enabled bioinformatics pipelines to improve gene fusion identification accuracy in clinical diagnostics
  • 5.5. Growth of lab-developed tests offering rapid gene fusion analysis for point-of-care oncology decision support
  • 5.6. Rising collaborations between diagnostic companies and pharmaceutical firms to co-develop fusion-driven therapeutic biomarkers
  • 5.7. Regulatory approvals for novel gene fusion detection kits accelerating market entry across emerging geographies
  • 5.8. Increasing utilization of RNA-based multiplex PCR assays for comprehensive detection of rare fusion transcripts in solid tumors
  • 5.9. Emergence of automated sample-to-report platforms reducing turnaround time for gene fusion analysis in clinical labs
  • 5.10. Investment trends fueling expansion of decentralized testing networks for gene fusion assays in community hospitals

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Fusion Testing Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Immunohistochemistry
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Next Generation Sequencing
    • 8.3.2. Transcriptome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Reverse Transcription Polymerase Chain Reaction

9. Gene Fusion Testing Market, by Sample Type

  • 9.1. Blood
    • 9.1.1. Plasma
    • 9.1.2. Serum
  • 9.2. Tissue
    • 9.2.1. Formalin Fixed Paraffin Embedded
    • 9.2.2. Fresh Frozen Tissue

10. Gene Fusion Testing Market, by Application

  • 10.1. Hematology
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
  • 10.2. Oncology
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Prostate Cancer
  • 10.3. Rare Diseases
    • 10.3.1. Developmental Disorders
    • 10.3.2. Neuromuscular Disorders

11. Gene Fusion Testing Market, by End User

  • 11.1. Diagnostic Laboratories
    • 11.1.1. Hospital Based Laboratories
    • 11.1.2. Independent Laboratories
  • 11.2. Hospitals
    • 11.2.1. Inpatient Facilities
    • 11.2.2. Outpatient Clinics
  • 11.3. Pharmaceutical Companies
    • 11.3.1. Biotechnology Companies
    • 11.3.2. Pharma Giants
  • 11.4. Research Institutions
    • 11.4.1. Academic Centers
    • 11.4.2. Private Research Laboratories

12. Gene Fusion Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Fusion Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Fusion Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Illumina, Inc.
    • 15.3.3. F. Hoffmann-La Roche Ltd
    • 15.3.4. Agilent Technologies, Inc.
    • 15.3.5. QIAGEN N.V.
    • 15.3.6. Bio-Rad Laboratories, Inc.
    • 15.3.7. NanoString Technologies, Inc.
    • 15.3.8. BGI Genomics Co., Ltd.
    • 15.3.9. Foundation Medicine, Inc.
    • 15.3.10. Archer DX, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENE FUSION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOL